Published in Tumori on September 02, 1997
The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev (2006) 2.36
The StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cells. Infect Immun (2005) 1.40
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol (2003) 1.16
Stromal IFN-γR-signaling modulates goblet cell function during Salmonella Typhimurium infection. PLoS One (2011) 1.08
Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance. World J Gastroenterol (2004) 1.04
Mucin overproduction in chronic inflammatory lung disease. Can Respir J (2006) 0.97
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J Ovarian Res (2014) 0.92
Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia (2002) 0.91
In-situ hybridization localized MUC7 mucin gene expression to the mucous acinar cells of human and MUC7-transgenic mouse salivary glands. Glycoconj J (1998) 0.81
Alterations in mucin expression in ovarian mucinous tumors: immunohistochemical analysis of MUC2, MUC5AC, MUC6, and CD10 expression. Acta Histochem Cytochem (2008) 0.79
The midgut epithelium of aquatic arthropods: a critical target organ in environmental toxicology. Environ Health Perspect (2002) 0.78
Differential Muc2 and Muc5ac secretion by stimulated guinea pig tracheal epithelial cells in vitro. Respir Res (2006) 0.77
Gastric Proteins MUC5AC and TFF1 as Potential Diagnostic Markers of Colonic Sessile Serrated Adenomas/Polyps. Am J Clin Pathol (2016) 0.75
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling). Biomolecules (2016) 0.75
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 3.80
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer (1996) 1.92
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
An internalized double-J catheter for percutaneous transgastric cystogastrostomy. AJR Am J Roentgenol (1989) 1.40
[The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Radiol Med (1997) 1.39
How alternative are immunoassay systems employing non-radioisotopic labels? A comparative appraisal of their main analytical characteristics. Q J Nucl Med (1995) 1.39
Partial trisomy 3p24.3 and partial monosomy 5p15.33: case report and a literature review. Genet Couns (2013) 1.38
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy (2013) 1.33
Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer (1992) 1.24
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol (2001) 1.17
Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori (1999) 1.17
Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer (1991) 1.16
Validity of a short insomnia questionnaire: the SDQ. Brain Res Bull (2004) 1.14
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Local recurrence after curative resection for colorectal cancer: frequency, risk factors and treatment. J Surg Oncol Suppl (1991) 1.10
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun (2004) 1.09
A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer (1998) 1.08
Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 1.08
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res (1985) 1.06
Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer (1992) 1.05
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04
Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia (2007) 1.04
The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg (1993) 1.04
Metabolic studies of blood infused into the myocardium. J Thorac Cardiovasc Surg (1967) 1.03
Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med (2001) 1.03
Cyclic peptides as non-carboxyl-terminal ligands of syntrophin PDZ domains. J Biol Chem (1998) 1.03
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging (2012) 1.01
Effect of lifestyle, smoking, and diet on development of intestinal metaplasia in H. pylori-positive subjects. Am J Gastroenterol (2001) 1.01
Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells. Oncogene (2006) 1.00
Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res (1999) 0.99
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med (1998) 0.99
Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging (2004) 0.98
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol (2002) 0.97
EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res (1997) 0.95
Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep (2000) 0.95
Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer (1987) 0.94
Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol (2011) 0.94
Sentinel lymph node mapping and biopsy for breast cancer: a review of the literature relative to 4791 procedures. Tumori (2000) 0.94
Circulating dendritic cells following burn. Burns (2009) 0.94
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med (1998) 0.93
MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging (2008) 0.93
Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol (2000) 0.92
Decrease of circulating dendritic cells in burn patients. Ann Burns Fire Disasters (2007) 0.92
Choroid plexus papilloma of the cerebellopontine angle: a twelve patient series. Surg Neurol (1999) 0.91
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol (2000) 0.91
A simple loop method for the automated preparation of (11C)raclopride from (11C)methyl triflate. Appl Radiat Isot (2001) 0.91
Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. J Clin Endocrinol Metab (1998) 0.90
Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med (1997) 0.90
Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors. Int J Biol Markers (2002) 0.89
The effect of paracetamol on nociception and dynorphin A levels in the rat brain. Neuropeptides (2001) 0.89
Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J Transl Med (2006) 0.88
The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori (1997) 0.88
The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer (1999) 0.88
(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging (2010) 0.88
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res (2000) 0.88
Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant (2008) 0.87
Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res (1996) 0.87
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers (2005) 0.87
A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res (2001) 0.87
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer (2004) 0.86
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem (1994) 0.86
A clinical trial of oral hyposensitization in systemic allergy to nickel. Int J Immunopathol Pharmacol (2006) 0.85
Circulating tumor markers in breast cancer (review). Anticancer Res (1990) 0.85
Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int J Biol Markers (1995) 0.85
The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res (2000) 0.85
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer (1995) 0.85
Methamphetamine alters prodynorphin gene expression and dynorphin A levels in rat hypothalamus. Eur J Pharmacol (1999) 0.85
Apple desensitization in two patients with PR-10 proteins allergy. Allergy (2009) 0.85
Comparative study of 15 lysosomal enzymes in chorionic villi and cultured amniotic fluid cells. Early prenatal diagnosis in seven pregnancies at risk for lysosomal storage diseases. Prenat Diagn (1986) 0.84
Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol (2001) 0.84
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat (2001) 0.84
Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers (1999) 0.84
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers (1999) 0.84
99Tcm-MIBI scintimammography in 300 consecutive patients: factors that may affect accuracy. Nucl Med Commun (1999) 0.84
Segmental dilatation of the ileum presenting with acute intestinal bleeding. J Pediatr Surg (2002) 0.84
Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother (1999) 0.83
A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides. Appl Radiat Isot (2000) 0.83
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol (2002) 0.83
Partial trisomy 10p12.33 and partial monosomy 13q32.1: case report and a literature review. Genet Couns (2011) 0.83